<p>投資者在 <strong>小野製藥 (ADR)</strong> (TSE:4528) 的一週表現良好，股價上漲了 7.1%，收於 JP¥2,479，此次上漲是在其年度業績發佈後發生的。JP¥5160 億的收入符合預期，儘管法定每股收益（EPS）為 JP¥148，低於預期，差距為 2.1%。收益報告對投資者來説非常重要，因為他們可以跟蹤公司的表現，查看分析師對明年的預測，並觀察對公司的情緒是否發生變化。因此，我們收集了最新的收益後預測，以瞭解明年的預期。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883"/></p>
<p>TSE:4528 收益和收入增長 2026 年 5 月 12 日</p>
<p>考慮到最新的業績結果，覆蓋小野製藥的 11 位分析師的當前共識是，預計 2027 年的收入為 JP¥454.2 億。這意味着小野製藥的收入在過去 12 個月中減少了 12%。法定每股收益預計在同一時期內將縮減 2.8%，降至 JP¥144。在此次收益報告之前，分析師們曾預測 2027 年的收入為 JP¥461.0 億，每股收益（EPS）為 JP¥142。共識分析師似乎沒有在這些結果中看到任何會改變他們對公司的看法的因素，因為他們的預估沒有發生重大變化。</p>
<p>查看我們對小野製藥的最新分析</p>
<p>因此，得知共識價格目標基本保持不變在 JP¥2,221 也就不足為奇了。共識價格目標只是各個分析師目標的平均值，因此，查看基礎估計的範圍可能會很有幫助。最樂觀的小野製藥分析師的目標價為每股 JP¥2,950，而最悲觀的則為 JP¥1,750。對該股票的看法確實存在差異，但我們認為估計範圍並不夠寬，以至於暗示情況無法預測。</p>
<p>我們可以從更大的背景來看待這些估計，例如這些預測與過去表現的對比，以及相對於行業內其他公司的預測是更樂觀還是更悲觀。這些估計暗示收入預計將放緩，預計到 2027 年底年化下降 12%。這表明與過去五年的年增長率 9.6% 相比，收入將顯著減少。與我們的數據相比，顯示同一行業的其他公司預計年收入增長 4.0%。顯然，小野製藥的收入預計將顯著低於更廣泛的行業。</p>
<h2>結論</h2>
<p>最明顯的結論是，近期業務前景沒有重大變化，分析師們保持了他們的收益預測，與之前的估計一致。好的一面是，收入預估沒有重大變化；儘管預測暗示它們的表現將低於更廣泛的行業。共識價格目標保持在 JP¥2,221，最新的估計不足以對他們的價格目標產生影響。</p>
<p>基於這一思路，我們認為業務的長期前景比明年的收益更為重要。我們有來自多位小野製藥分析師的估計，直到 2029 年，您可以在我們的平台上免費查看。</p>
<p>我們不想過於潑冷水，但我們確實發現了 <strong>小野製藥的 1 個警示信號</strong>，您需要注意。</p>
<h3><strong>新：AI 股票篩選器和警報</strong></h3>
<p>我們的新 AI 股票篩選器每天掃描市場，以發現機會。</p>
<p>• 股息強勁的公司（3%+ 收益）</p>
<p>• 內部人士購買的被低估小型股</p>
<p>• 高增長的科技和 AI 公司</p>
<p>或者從 50 多個指標中構建您自己的篩選器。</p>
<p>立即免費探索</p>

4528

小野制藥(ADR)

<p>大野製藥株式會社（TSE:4528）在發佈年度報告後，股價上漲 7.1%，達到 2,479 日元，收入為 5160 億日元，符合預期，但每股收益（EPS）為 148 日元，低於預期 2.1%。分析師預測，2027 年收入將下降 12%，降至 4542 億日元，EPS 預計將下降 2.8%，降至 144 日元。共識目標價維持在 2,221 日元，範圍在 1,750 日元至 2,950 日元之間。總體而言，分析師認為業務前景沒有重大變化，儘管收入增長預計將落後於行業平均水平</p>

<p>Investors in <strong>Ono Pharmaceutical Co., Ltd.</strong> (TSE:4528) had a good week, as its shares rose 7.1% to close at JP¥2,479 following the release of its yearly results. Revenues of JP¥516b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at JP¥148, missing estimates by 2.1%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p>投資者在 <strong>小野製藥 (ADR)</strong> (TSE:4528) 的一週表現良好，股價上漲了 7.1%，收於 JP¥2,479，此次上漲是在其年度業績發佈後發生的。JP¥5160 億的收入符合預期，儘管法定每股收益（EPS）為 JP¥148，低於預期，差距為 2.1%。收益報告對投資者來説非常重要，因為他們可以跟蹤公司的表現，查看分析師對明年的預測，並觀察對公司的情緒是否發生變化。因此，我們收集了最新的收益後預測，以瞭解明年的預期。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883" alt="" original-src="https://images.simplywall.st/asset/chart/876950-earnings-and-revenue-growth-1-dark-2/1778622656883"/></p>
<p>TSE:4528 Earnings and Revenue Growth May 12th 2026</p>
<div class="lb-trans"><p>TSE:4528 收益和收入增長 2026 年 5 月 12 日</p>
</div><p>Taking into account the latest results, the current consensus, from the eleven analysts covering Ono Pharmaceutical, is for revenues of JP¥454.2b in 2027. This implies a considerable 12% reduction in Ono Pharmaceutical's revenue over the past 12 months. Statutory earnings per share are expected to shrink 2.8% to JP¥144 in the same period. Before this earnings report, the analysts had been forecasting revenues of JP¥461.0b and earnings per share (EPS) of JP¥142 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.</p>
<div class="lb-trans"><p>考慮到最新的業績結果，覆蓋小野製藥的 11 位分析師的當前共識是，預計 2027 年的收入為 JP¥454.2 億。這意味着小野製藥的收入在過去 12 個月中減少了 12%。法定每股收益預計在同一時期內將縮減 2.8%，降至 JP¥144。在此次收益報告之前，分析師們曾預測 2027 年的收入為 JP¥461.0 億，每股收益（EPS）為 JP¥142。共識分析師似乎沒有在這些結果中看到任何會改變他們對公司的看法的因素，因為他們的預估沒有發生重大變化。</p>
</div><p>Check out our latest analysis for Ono Pharmaceutical</p>
<div class="lb-trans"><p>查看我們對小野製藥的最新分析</p>
</div><p>It will come as no surprise then, to learn that the consensus price target is largely unchanged at JP¥2,221. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Ono Pharmaceutical analyst has a price target of JP¥2,950 per share, while the most pessimistic values it at JP¥1,750. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.</p>
<div class="lb-trans"><p>因此，得知共識價格目標基本保持不變在 JP¥2,221 也就不足為奇了。共識價格目標只是各個分析師目標的平均值，因此，查看基礎估計的範圍可能會很有幫助。最樂觀的小野製藥分析師的目標價為每股 JP¥2,950，而最悲觀的則為 JP¥1,750。對該股票的看法確實存在差異，但我們認為估計範圍並不夠寬，以至於暗示情況無法預測。</p>
</div><p>Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 12% by the end of 2027. This indicates a significant reduction from annual growth of 9.6% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 4.0% per year. It's pretty clear that Ono Pharmaceutical's revenues are expected to perform substantially worse than the wider industry.</p>
<div class="lb-trans"><p>我們可以從更大的背景來看待這些估計，例如這些預測與過去表現的對比，以及相對於行業內其他公司的預測是更樂觀還是更悲觀。這些估計暗示收入預計將放緩，預計到 2027 年底年化下降 12%。這表明與過去五年的年增長率 9.6% 相比，收入將顯著減少。與我們的數據相比，顯示同一行業的其他公司預計年收入增長 4.0%。顯然，小野製藥的收入預計將顯著低於更廣泛的行業。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at JP¥2,221, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>最明顯的結論是，近期業務前景沒有重大變化，分析師們保持了他們的收益預測，與之前的估計一致。好的一面是，收入預估沒有重大變化；儘管預測暗示它們的表現將低於更廣泛的行業。共識價格目標保持在 JP¥2,221，最新的估計不足以對他們的價格目標產生影響。</p>
</div><p>Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Ono Pharmaceutical analysts - going out to 2029, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>基於這一思路，我們認為業務的長期前景比明年的收益更為重要。我們有來自多位小野製藥分析師的估計，直到 2029 年，您可以在我們的平台上免費查看。</p>
</div><p>We don't want to rain on the parade too much, but we did also find <strong>1 warning sign for Ono Pharmaceutical</strong> that you need to be mindful of.</p>
<div class="lb-trans"><p>我們不想過於潑冷水，但我們確實發現了 <strong>小野製藥的 1 個警示信號</strong>，您需要注意。</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票篩選器和警報</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我們的新 AI 股票篩選器每天掃描市場，以發現機會。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 股息強勁的公司（3%+ 收益）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 內部人士購買的被低估小型股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增長的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者從 50 多個指標中構建您自己的篩選器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免費探索</p>
</div>

分析師預測：以下是經紀人對小野製藥 (ADR) (TSE:4528) 年度報告後的看法